Business Description
Nuvation Bio Inc
NAICS : 541713
SIC : 2834
ISIN : US67080N1019
Share Class Description:
NUVB: Ordinary Shares - Class ATotal Employee Number:
307Description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.34 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.46 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.09 | |||||
Beneish M-Score | 6.91 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -0.1 | |||||
3-Year EPS without NRI Growth Rate | -4.7 | |||||
3-Year FCF Growth Rate | -6.1 | |||||
3-Year Book Growth Rate | -33.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 83.03 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 83.12 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.82 | |||||
9-Day RSI | 55.08 | |||||
14-Day RSI | 56.18 | |||||
3-1 Month Momentum % | 6.87 | |||||
6-1 Month Momentum % | -45.48 | |||||
12-1 Month Momentum % | 131.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.44 | |||||
Quick Ratio | 7.24 | |||||
Cash Ratio | 6.71 | |||||
Days Inventory | 185.51 | |||||
Days Sales Outstanding | 25.63 | |||||
Days Payable | 443.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.6 | |||||
Shareholder Yield % | -2.33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 90.78 | |||||
Operating Margin % | -104.99 | |||||
Net Margin % | -102.06 | |||||
EBITDA Margin % | -86.47 | |||||
FCF Margin % | -93.72 | |||||
OCF Margin % | -87.9 | |||||
ROE % | -41.87 | |||||
ROA % | -24.78 | |||||
ROIC % | -316.5 | |||||
3-Year ROIIC % | -153.36 | |||||
ROC (Joel Greenblatt) % | -2548.22 | |||||
ROCE % | -24.19 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 14.6 | |||||
PB Ratio | 6.25 | |||||
Price-to-Tangible-Book | 6.46 | |||||
EV-to-EBIT | -12.14 | |||||
EV-to-EBITDA | -12.33 | |||||
EV-to-Revenue | 10.67 | |||||
EV-to-Forward-Revenue | 7.42 | |||||
EV-to-FCF | -11.38 | |||||
| Price-to-Net-Current-Asset-Value | 6.57 | |||||
| Price-to-Net-Cash | 8.16 | |||||
Earnings Yield (Greenblatt) % | -8.24 | |||||
FCF Yield % | -6.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:NUVB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Nuvation Bio Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 143.046 | ||
| EPS (TTM) ($) | -0.43 | ||
| Beta | 1.9619 | ||
| 3-Year Sharpe Ratio | 0.77 | ||
| 3-Year Sortino Ratio | 1.58 | ||
| Volatility % | 90.91 | ||
| 14-Day RSI | 56.18 | ||
| 14-Day ATR ($) | 0.408126 | ||
| 20-Day SMA ($) | 5.427 | ||
| 12-1 Month Momentum % | 131.73 | ||
| 52-Week Range ($) | 2.0326 - 9.75 | ||
| Shares Outstanding (Mil) | 348.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuvation Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nuvation Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:00 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 30 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:55 | 4.90 (-1.01%) | ||
| TD Cowen\'s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-26 12:00 | 4.72 (-2.28%) | ||
| General meeting for 2026 | 2026-05-21 11:00 | 4.51 (+4.88%) | ||
| Guidance call for 2026 | 2026-05-20 09:00 | 4.24 (+0.95%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 13:30 | 4.21 (-2.55%) | ||
| Guidance call for 2026 | 2026-05-13 08:00 | 4.84 (+1.89%) |
Show
Entries
Nuvation Bio Inc Frequently Asked Questions
What is Nuvation Bio Inc(NUVB)'s stock price today?
The current price of NUVB is $5.75. The 52 week high of NUVB is $9.75 and 52 week low is $2.03.
When is next earnings date of Nuvation Bio Inc(NUVB)?
The next earnings date of Nuvation Bio Inc(NUVB) is 2026-08-07 Est..
Does Nuvation Bio Inc(NUVB) pay dividends? If so, how much?
Nuvation Bio Inc(NUVB) does not pay dividend.
Guru Commentaries on NYSE:NUVB
No articles.
Press Release
Articles on Nuvation Bio Inc
No articles.
Headlines
See More- 1
Jul 06, 2026
Nuvation Bio ups convertible notes offering to $287.5M after greenshoe exercise
Seeking Alpha • 4:30pm
Jun 26, 2026
Nuvation Bio prices $250M convertible notes offering
Seeking Alpha • 12:38am
Jun 25, 2026
Nuvation Bio to offer $200M convertible senior notes
Seeking Alpha • 6:12am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers